Novel Drug Shows Promise as First-Line Parkinson’s Treatment

An experimental drug that combines low-dose extended-release pramipexole and rasagiline showed strong efficacy in early-stage Parkinson's disease — with less sleepiness — in a new phase 3 trial.
Medscape Medical News